CVS Health sets November 4 results date. CVS Health stock falls 1.23 percent

Published on 10/08/2026 at 16:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 7.30 percent to USD 106.10 billion. CVS Health stock costs EUR 77.62 on October 8, 2026 after EUR 78.59.

Key points in brief

CVS Health set November 4, 2026, for its third-quarter results call.
The second quarter produced USD 106.10 billion in revenue, up 7.30 percent year over year.
The Lang & Schwarz price was EUR 77.62 on October 8, 2026, down 1.23 percent from EUR 78.59.
MarketBeat reported a Moderate Buy consensus with an average USD 107.24 target.

Moderner Apothekenverkaufsraum mit Apothekerin und Kundin vor Medikamentenregalen — CVS Health Corp. zeigt fotorealen Apothekenverkaufsraum mit Apothekerin und Kundin, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health (ISIN US1266501006) set November 4, 2026, for its third-quarter results conference call, according to CVS Health on October 5, 2026. At Lang & Schwarz, the stock was trading at EUR 77.62 on October 8, 2026 at 4:37 p.m. CEST, down 1.23 percent versus the prior close of EUR 78.59.

Three milestones shape the story

On October 29, 2025, CVS Health reported quarterly revenue of USD 102.90 billion, according to Ticker Scout. The figure marked a 7.80 percent year-over-year increase and provides the earlier reference point for the company recovery narrative.

On August 5, 2026, second-quarter revenue reached USD 106.10 billion, up 7.30 percent year over year, while GAAP diluted earnings per share rose to USD 2.31 from USD 0.80 in the prior-year quarter, according to Ticker Scout.

On October 5, 2026, CVS Health announced the November 4 conference call at 8:00 a.m. ET. The company said the call will cover third-quarter 2026 results, giving the next reporting date a concrete place on the calendar.

What does the distribution deal change?

McKesson agreed in principle on October 1, 2026, to extend its pharmaceutical distribution partnership with CVS Health through June 2032, according to Investing.com. The arrangement covers CVS mail-order, specialty and retail pharmacies as well as distribution centers, extending the existing relationship beyond June 2027.

The earnings backdrop also includes stronger cash generation. CVS Health reported USD 10.60 billion in year-to-date operating cash flow for the second quarter of 2026 and raised full-year adjusted earnings guidance to USD 7.90-8.10 per share, according to Ticker Scout.

Dates and analyst expectations

CVS Health is scheduled to discuss third-quarter results on November 4, 2026, at 8:00 a.m. ET, according to CVS Health. A Form 10-Q filing is expected on October 28, 2026, according to Ticker Scout.

MarketBeat reported on October 3, 2026, that Wall Street Zen had lowered its rating from strong buy to buy. The broader analyst tally stood at 22 Buy ratings and one Hold rating, with an average price target of USD 107.24, according to MarketBeat. That target is a separate US-dollar reference and is not combined with the Lang & Schwarz euro quotation.

Stock trades below its yearly high

CVS Health has a market capitalization of USD 110.9 billion as of October 8, 2026. Its primary NYSE quotation stood at USD 86.95 at 2:45 p.m. UTC on October 8, 2026, while the 52-week range was USD 69.51 to USD 110.68.

The current euro quotation remains below the prior Lang & Schwarz close, while the latest operating figures show revenue growth and higher quarterly GAAP earnings per share. The November reporting date will provide the next quantified test of that improvement.

The further course of trading is shown by the continuously updated real-time quote of CVS Health stock.